CN113925846A - Black plaster suitable for acute soft tissue injury and preparation method thereof - Google Patents
Black plaster suitable for acute soft tissue injury and preparation method thereof Download PDFInfo
- Publication number
- CN113925846A CN113925846A CN202111230297.7A CN202111230297A CN113925846A CN 113925846 A CN113925846 A CN 113925846A CN 202111230297 A CN202111230297 A CN 202111230297A CN 113925846 A CN113925846 A CN 113925846A
- Authority
- CN
- China
- Prior art keywords
- formula
- myrrh
- soft tissue
- oil
- sesame oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011505 plaster Substances 0.000 title claims abstract description 54
- 230000001154 acute effect Effects 0.000 title claims abstract description 30
- 208000026137 Soft tissue injury Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 104
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 57
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 57
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 55
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 35
- 229940079593 drug Drugs 0.000 claims abstract description 34
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 33
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 31
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000004863 Frankincense Substances 0.000 claims abstract description 28
- 229940116229 borneol Drugs 0.000 claims abstract description 28
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 28
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 27
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 27
- 241000402754 Erythranthe moschata Species 0.000 claims abstract description 27
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 27
- 239000009136 dragon's blood Substances 0.000 claims abstract description 27
- 239000003292 glue Substances 0.000 claims abstract description 27
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 5
- 240000004824 Trimezia steyermarkii Species 0.000 claims abstract 5
- 239000008159 sesame oil Substances 0.000 claims description 56
- 235000011803 sesame oil Nutrition 0.000 claims description 56
- 239000003921 oil Substances 0.000 claims description 30
- 235000019198 oils Nutrition 0.000 claims description 30
- 239000002674 ointment Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 25
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 25
- 241000219061 Rheum Species 0.000 claims description 24
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 23
- 235000011477 liquorice Nutrition 0.000 claims description 23
- 244000061520 Angelica archangelica Species 0.000 claims description 19
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 19
- 238000010438 heat treatment Methods 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 14
- 240000004980 Rheum officinale Species 0.000 claims description 13
- 235000008081 Rheum officinale Nutrition 0.000 claims description 13
- 238000002791 soaking Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 238000002844 melting Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 241000382455 Angelica sinensis Species 0.000 claims description 5
- 241000735470 Juncus Species 0.000 claims description 5
- 241001330502 Stephania Species 0.000 claims description 4
- 238000003892 spreading Methods 0.000 claims description 4
- 230000007480 spreading Effects 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 claims 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 238000010521 absorption reaction Methods 0.000 abstract description 12
- 230000000202 analgesic effect Effects 0.000 abstract description 8
- 206010067484 Adverse reaction Diseases 0.000 abstract description 7
- 230000006838 adverse reaction Effects 0.000 abstract description 7
- 239000011159 matrix material Substances 0.000 abstract description 5
- 239000011148 porous material Substances 0.000 abstract description 5
- 241001676573 Minium Species 0.000 abstract description 4
- 230000036592 analgesia Effects 0.000 abstract description 4
- 238000010579 first pass effect Methods 0.000 abstract description 4
- 230000001976 improved effect Effects 0.000 abstract description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 3
- 201000004624 Dermatitis Diseases 0.000 abstract description 3
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract description 3
- 208000003455 anaphylaxis Diseases 0.000 abstract description 3
- 239000000853 adhesive Substances 0.000 abstract description 2
- 230000001070 adhesive effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 230000008338 local blood flow Effects 0.000 abstract description 2
- 239000012466 permeate Substances 0.000 abstract description 2
- 244000081426 Ranunculus ficaria Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 33
- 229960001138 acetylsalicylic acid Drugs 0.000 description 33
- 230000036407 pain Effects 0.000 description 25
- 208000002193 Pain Diseases 0.000 description 24
- 244000186071 dragons blood palm Species 0.000 description 23
- 241000736199 Paeonia Species 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 17
- 239000008280 blood Substances 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 235000013871 bee wax Nutrition 0.000 description 12
- 239000012166 beeswax Substances 0.000 description 12
- 230000008961 swelling Effects 0.000 description 12
- 239000013641 positive control Substances 0.000 description 11
- 239000001993 wax Substances 0.000 description 11
- 206010042674 Swelling Diseases 0.000 description 10
- 206010007247 Carbuncle Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 230000037040 pain threshold Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 206010010774 Constipation Diseases 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 201000000736 Amenorrhea Diseases 0.000 description 6
- 206010001928 Amenorrhoea Diseases 0.000 description 6
- 231100000540 amenorrhea Toxicity 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 230000008736 traumatic injury Effects 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 235000018062 Boswellia Nutrition 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 244000003187 Juncus effusus Species 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 201000009032 substance abuse Diseases 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000208229 Burseraceae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 206010053155 Epigastric discomfort Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000001414 Eucalyptus viminalis Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 244000153234 Hibiscus abelmoschus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 241001416180 Moschidae Species 0.000 description 2
- 208000000592 Nasal Polyps Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 241001106477 Paeoniaceae Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 241001530126 Scrophularia Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000028659 discharge Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 240000000572 Blumea balsamifera Species 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 241000142952 Hamamelidaceae Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 241000731961 Juncaceae Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000972159 Moschus chrysogaster Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000207960 Pedaliaceae Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 231100000674 Phytotoxicity Toxicity 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 241001121987 Scrophularia ningpoensis Species 0.000 description 1
- 241000207844 Scrophulariaceae Species 0.000 description 1
- 241000593775 Serissa Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229910052956 cinnabar Inorganic materials 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000010446 mirabilite Substances 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 208000018962 mouth sore Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000009112 niuhuang Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 208000007645 potassium deficiency Diseases 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical group 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/241—Lead; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Insects & Arthropods (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a black plaster suitable for acute soft tissue injury and capable of safely and rapidly achieving effective analgesia and a preparation method thereof, and the black plaster is characterized by being prepared from Chinese angelica, dahurian angelica root, figwort root, rhubarb, red paeony root, liquoric root, myrrh, dragon's blood, yellow wax, white glue, red lead, borneol, musk, frankincense and the like which are used as raw materials in proportion; the formula and the preparation process are scientific and reasonable, and the utilization rate and the drug effect of the formula drug can be effectively improved; the minium which has the function of the adhesive can also combine the effective components in the traditional Chinese medicine with the minium to enable the effective components to be in closer contact with pores, and the effective components can quickly permeate the pores to enter local blood circulation; the external transdermal absorption has no first-pass effect and high drug utilization rate; the black plaster matrix has mild drug property, and effectively reduces skin allergy and anaphylactic reaction; the traditional Chinese medicine composition has the same analgesic effect as an oral medicine, is safer, has small side effect and greatly reduces the incidence rate of adverse reactions; can be applied to the affected part for a long time, and has lasting effect; has good analgesic and anti-inflammatory effects.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine preparations, in particular to an external plaster, and especially relates to a black plaster suitable for acute soft tissue injury and a preparation method thereof.
Background
In the past, intravenous injection is often selected by common people for the purpose of relieving symptoms and pain as quickly as possible. However, intravenous injection accounts for more than half of the incidence of adverse drug reactions. The main reason is that the medicine directly enters blood circulation from a special way of intravenous infusion, and is not filtered by a natural barrier of a human body, so that the medicine effect is exerted too fast, and the adverse reaction is quicker and more serious. Even under the most strict operation environment, the infusion process is difficult to avoid carrying particles, and the particles can accumulate in the capillaries of organs such as heart, lung, liver, kidney and the like after entering a human body, thereby causing serious diseases such as vascular embolism, pulmonary hypertension and the like, and further causing local blood supply insufficiency, tissue ischemia, hypoxia, edema, inflammation, anaphylactic reaction and the like. Adverse drug reactions caused by intravenous administration are not easy to be seen, and the body immunity can be reduced and the drug resistance of bacteria can be induced by frequent transfusion. Some treatment options such as intravenous injection waste medical resources, more than 80% of infusion prescriptions are antibiotics for resisting bacteria and diminishing inflammation, and abuse phenomena are common. Meanwhile, the price of the medicine is high, and the treatment cost is increased.
In recent years, under the advocation of 'reducing intravenous infusion' of world health organization, many provinces of China begin to implement a policy scheme of stopping infusion in outpatient service at present, so that the abuse of antibacterial drugs is gradually prevented and the occurrence of phytotoxicity is reduced. People abandon 'infusion' and select other medicines for administration when mild symptoms occur. Most of the existing medicines are oral medicines and are completed through gastrointestinal tract digestive system and liver metabolism. All oral drugs are absorbed through the gastrointestinal wall. And then into the portal vein. Some drugs have little metabolic effect, and some drugs are metabolized and eliminated widely in the gastrointestinal wall or liver. The first-pass action enhances the metabolism, reduces the amount of drug entering the systemic circulation and the absorption, resulting in a reduced therapeutic effect. Increasing the oral dosage to saturate the drug metabolism and overcome the consumption of the first-pass action is also a waste of medical resources and does not actually improve the bioavailability. And the oral medicine also has adverse reaction, and the higher the dosage, the higher the possibility of adverse reaction and the more serious the degree.
The parenteral administration route avoiding the first pass effect can be used for obtaining the medicine by percutaneous absorption except injection. Transdermal absorption of a drug refers to the process by which the drug passes through the epidermis, is absorbed by the capillaries and lymph into the systemic circulation. The transdermal absorption process of the medicine mainly comprises three stages of release, penetration and absorption into the blood circulation. Refers to the process of absorption of the drug applied to the skin through the sweat gland channel, transport through the stratum corneum and transport through the deep epidermis. Release refers to the release of the drug from the matrix and diffusion to the skin or mucosal surface. The famous medicine Xuanxi says that the property of a drug can enter into the skin and muscle from the pores, clear the meridians, or be extracted or be attacked to disperse, especially when being taken, it is said to be magical in magical way by sticking the paste to block the qi. Ancient people had a discussion of "skin separation and hair opening", which indicates that the external application of Chinese herbs can be absorbed through skin to achieve the effects of regulating qi, harmonizing yin and yang and dredging viscera. The percutaneous absorption type medicine achieves the purposes of medication and treatment through the action of skin absorption.
The plaster is one of five Chinese medicine preparations, i.e. pill, powder, ointment, pellet and soup. As the name implies, a paste is a viscous substance. The paste is a solid, semisolid or semi-fluid preparation at normal temperature. Consists of two parts of a drug and a matrix (also without the matrix). The black plaster is an external preparation for being pasted on skin, which is prepared by refining medicinal materials, edible vegetable oil and red lead into paste and spreading the paste on a backing material. It has protective, sealing and therapeutic effects, thick ointment layer, and long-lasting effect. Black plaster appears in the Wen and jin period, the preparation of Tang and Song is gradually improved and widely used, and the Mingqing period is one of the common medicines. In recent times, the use of black plaster is greatly reduced due to the development of decoction. After the rubber plaster of modern technology appeared, black plaster was almost completely disappointed from hospitals and only circulated in civilian.
According to modern pharmacological research, the black plaster is superior to the rubber plaster in absorption and curative effect. Because the manufacturing process of the black plaster is complex and the quality control is not easy to carry out, the traditional Chinese medicine external application is carried out in traditional Chinese medicine hospitals, namely, the Chinese herbal medicines are crushed and then added with matrixes such as honey, vaseline and the like to be externally applied in an ointment shape, and then the medicines are fixed by cotton paper and bandages, the medicine is changed every 24 hours, and the use cost is high. The black plaster can be used for 3 to 15 days after being pasted for a long time, and can be pasted again after being taken off, so that the curative effect is not influenced, and the cost is lower.
The transdermal absorption is adopted, and the transdermal drug delivery system has the advantages of removing the first pass effect of the liver and avoiding the chemical and biological effects of the drug on the lower gastrointestinal tract. With the rapid development of the research of Transdermal Drug Delivery System (TDDS), the application range of the external ointment is wider.
Aspirin,2- (acetoxy) benzoic acid, also known as acetylsalicylic acid. Is a white crystal or crystalline powder, has no odor or slight acetic acid odor, is slightly soluble in water, is easily soluble in ethanol, is soluble in diethyl ether and chloroform, and has acidic aqueous solution. The product is a salicylic acid derivative, and clinical application for nearly a hundred years proves that the product has better effect on relieving mild or moderate pain, such as toothache, headache, neuralgia, muscular soreness and dysmenorrheal. It is also used for treating fever due to common cold and influenza, and rheumatalgia. In recent years, aspirin has an inhibiting effect on platelet aggregation and can prevent thrombosis, and the aspirin is clinically used for preventing transient ischemic attack, myocardial infarction, artificial heart valves and venous fistula or the formation of thrombosis after other operations. Aspirin is a long-standing antipyretic analgesic. Because of easy absorption after oral administration, the aspirin oral liquid has wide tissue distribution and strong effect on the whole body, and the adverse reactions of the aspirin are gradually increased along with the wide application of the aspirin.
Gastrointestinal symptoms are the most common adverse reactions of aspirin, and the more common symptoms are nausea, vomiting, epigastric discomfort or pain and the like. Oral aspirin can directly stimulate gastric mucosa to cause epigastric discomfort, nausea and vomiting. The long-term use of the medicine is easy to cause gastric mucosa injury, gastric ulcer and gastrorrhagia. Blood images, fecal occult blood tests and necessary gastroscopy should be monitored frequently after long-term use. Aspirin is preferably taken after meal or together with antacid, and should be used with cautions or not for ulcer patients. The medicine for enhancing the barrier function of the gastric mucosa, such as misoprostol, has special effect on peptic ulcer caused by non-steroidal anti-inflammatory drugs, such as aspirin. Patients with specific physique can cause allergic reactions such as rash, angioneurotic edema and asthma after taking aspirin, and are often seen in middle-aged people or patients with rhinitis and nasal polyp. Aspirin inhibits the production of prostaglandins, and is also associated with its effects on the immune system. Most of the asthma is serious and persistent, but generally, the antiasthmatic drugs are mostly ineffective and only have good hormone effect. Classic aspirin triple (aspirin intolerance, asthma and nasal polyps) may also occur. The nervous symptoms generally appear when the dosage is large, so-called salicylic acid reaction appears, the symptoms are headache, dizziness, tinnitus and visual and audio power decline, when the dosage is too large, confusion, convulsion, even coma and the like can appear, and the symptoms can be completely recovered 2 to 3 days after the medicine is stopped. High doses may also cause central nausea and vomiting. Aspirin induced liver damage commonly occurs when applied at high doses. This lesion is not an acute effect and is characterized by the fact that it occurs several months after treatment, usually asymptomatic, with some patients presenting discomfort and tenderness to the upper right of the abdomen. Serum liver enzyme levels are elevated, but significant jaundice is not common. The damage is reversible after aspirin is stopped, serum transaminase mostly returns to normal within 1 month after the aspirin is stopped, and the liver damage is easy to occur in children with systemic rheumatoid disease compared with other two types of rheumatism. After aspirin causes liver damage, the clinical treatment method is to stop taking the medicine, and amino acid fluid infusion, VitC, inosine and other medicines are taken, so that the symptoms generally disappear after 1 week. Interstitial nephritis, renal papilla necrosis, and renal hypofunction may occur with long-term use of aspirin. After long-term administration, the product can cause oxidative phosphorylation and uncoupling, potassium escapes from renal tubular cells, so potassium deficiency and overhigh uric acid discharge in urine are caused, and protein, cells, casts and the like can appear in lower-section urine with great damage. It is believed that some renal pelvis cancers are secondary complications of abuse of analgesics such as aspirin. Aspirin does not generally change the number of white blood cells and platelets, as well as the hematocrit and hemoglobin content. But chronic aspirin use can lead to iron deficiency anemia. Therapeutic doses of aspirin have no significant direct effect on the cardiovascular system. Large doses may act directly on vascular smooth muscle, resulting in peripheral vasodilation. Toxic doses may inhibit circulation by direct and central vasomotor paralysis. Aspirin may cause rayleigh syndrome when applied to children's influenza or varicella therapy. The reich syndrome is an acute encephalopathy and liver fatty infiltration syndrome, often occurring after certain acute viral infections. The etiology is not clear, but is generally thought to be related to the following factors: such as viruses (influenza virus and varicella virus), salicylate, exogenous viruses (aflatoxin), intrinsic metabolic defect, etc., and all factors can exist together or are caused by mutual influence among all factors. Aspirin is not advocated for clinical viral colds. Cross-allergic reactions can also be caused. The product is allergic to another salicylic acid drug. However, those allergic to this product are not always allergic to nonacetylated salicylic acid drugs.
Disclosure of Invention
The invention aims to provide a black plaster which can safely and quickly achieve effective analgesic effect and is suitable for acute soft tissue injury and a preparation method thereof.
The invention adopts the following technical scheme to realize the aim, and the black plaster suitable for acute soft tissue injury is prepared from the following raw materials in parts by weight:
the formula I is as follows: 25 to 35g of angelica, 25 to 35g of angelica dahurica, 25 to 35g of radix scrophulariae, 25 to 35g of rhubarb, 25 to 35g of red peony root and 25 to 35g of liquorice;
and the formula II comprises: 150 to 250g of myrrh, 150 to 250g of dragon's blood, 150 to 250g of yellow wax, 150 to 250g of white glue and 200 to 300g of red lead;
the formula III is as follows: 40 to 60g of borneol, 40 to 60g of musk, 40 to 60g of frankincense, 40 to 60g of myrrh and 40 to 60g of rush;
600-700 g of sesame oil.
The black plaster suitable for acute soft tissue injury comprises the following raw materials in parts by weight:
the formula I is as follows: 30 to 35g of angelica, 25 to 30g of angelica dahurica, 30 to 35g of radix scrophulariae, 25 to 30g of rhubarb, 30 to 35g of red peony root and 25 to 30g of liquorice;
and the formula II comprises: 200 to 250g of myrrh, 180 to 200g of dragon's blood, 200 to 250g of yellow wax, 220 to 250g of white glue and 200 to 250g of red lead;
the formula III is as follows: 45 to 55g of borneol, 45 to 50g of musk, 50 to 60g of frankincense, 50 to 60g of myrrh and 50 to 60g of rush;
630-700 g of sesame oil.
Preferably, the black plaster for acute soft tissue injury comprises the following raw materials in parts by weight:
the formula I is as follows: 30g of angelica, 30g of angelica dahurica, 30g of radix scrophulariae, 25g of rhubarb, 30g of red peony root and 25g of liquorice;
and the formula II comprises: 200g of myrrh, 200g of dragon's blood, 250g of yellow wax, 250g of white glue and 200g of red lead;
the formula III is as follows: 50g of borneol, 45g of musk, 60g of frankincense, 60g of myrrh and 50g of juncus effuses;
700g of sesame oil.
The rhubarb of the invention is raw rhubarb.
The preparation method of the black plaster suitable for acute soft tissue injury comprises the following steps:
the technical scheme includes that the first-component raw material medicines (Chinese angelica, dahurian angelica root, figwort root, raw rhubarb, red paeony root and liquoric root) are crushed and mixed according to a ratio, and an obtained first-component medicine mixture is put into sesame oil in a container and is uniformly stirred;
heating the oil-medicine mixture in the container and heating the oil-medicine mixture in the container, and continuously stirring the mixture to ensure that the composition-medicine mixture in the sesame oil is heated uniformly and fried to be withered and yellow (the oil color is dark brown, the inner part is scorched and the oil is not carbonized), and filtering dregs of the medicine to obtain filtered oil;
thirdly, adding the second raw material medicine (myrrh, dragon's blood, yellow wax and white glue) into the oil filter obtained in the second step according to the proportion, heating to 300-330 ℃ (320 ℃) and decocting to form water dripping beading to obtain medicinal oil;
fourthly, the medicinal oil is continuously heated for 5-10 minutes and is continuously stirred, so that oxides generated by the medicinal oil and the medicinal mixture of the second formula are promoted to be evaporated, impurities in the medicinal oil are reduced to the minimum extent, and the quality of the ointment is improved; then, the mixture is taken out of the fire when the temperature is between 300 and 360 ℃, lead is evenly sieved when the oil temperature is reduced to between 250 and 270 ℃, and the mixture is stirred along one direction, so that the lead is combined with the medicinal oil, and the lead is prevented from floating on the oil surface or being deposited on the bottom of grains, and the full reaction is carried out;
fifthly, pouring the obtained ointment into water for soaking for removing fire toxin, avoiding skin irritation, erythema, pruritus and even blistering ulcer, and condensing for later use;
sixthly, crushing the three raw materials (borneol, musk, frankincense, myrrh and juncus effusus) into fine powder, mixing uniformly, and sieving, wherein the condensed ointment obtained in the step is divided according to the parts by weight for later use;
taking the ointment out of the water, heating and melting the ointment to remove water vapor, cooling the ointment to 70-80 ℃, adding the ointment into the medicinal powder obtained in the step sixteenth according to the proportion, and uniformly stirring the ointment; spreading and coating to obtain the finished product.
The method comprises the following steps of: 25 to 35g of angelica, 25 to 35g of angelica dahurica, 25 to 35g of radix scrophulariae, 25 to 35g of rhubarb, 25 to 35g of red peony root, 25 to 35g of liquorice and 600 to 700g of sesame oil; the formula II in the step III comprises 150-250 g of myrrh, 150-250 g of dragon's blood, 150-250 g of yellow wax, 150-250 g of white glue and 200-300 g of red lead; the formula III in the step VI is prepared from 40g to 60g of borneol, 40g to 60g of musk, 40g to 60g of frankincense, 40g to 60g of myrrh and 40g to 60g of rush.
In the steps, sesame oil is preheated to 40-80 ℃ before a medicine mixture in a composition is put into the sesame oil; after the composition I medicine mixture is put into sesame oil, soaking for 1 to 1.5 hours at the temperature of between 90 and 100 ℃ in a heat preservation way, namely heating the container and the oil-medicine mixture in the container in a water bath, and avoiding the situation that hard parts in the composition I medicine mixture are not penetrated and the medicine effect cannot be fully exerted; heating the sesame oil to 220-240 ℃ (230 ℃) for 1-3.5 hours.
The step of the invention comprises soaking the Chinese medicinal paste in water for 24 hours; the temperature for heating and melting the stephania ointment is not more than 100 ℃.
Angelica sinensis is dried root of Angelica sinensis (Oliv.) Diels of Umbelliferae. The root of the whole angelica is slightly cylindrical and is divided into three parts by people, wherein the head part at the upper end of the root is called 'the head part', the main root at the middle part is called 'the body part' or 'the cun body', the branch root at the tail part is called 'the tail part' or 'the leg part', and the whole is called 'the whole body'. Whole Chinese angelica root, radix Angelicae sinensis can nourish blood and promote blood circulation. It is often used for treating blood deficiency, sallow complexion, giddiness, palpitation, menoxenia, amenorrhea, dysmenorrhea, asthenia cold, abdominal pain, constipation due to intestinal dryness, rheumatalgia, traumatic injury, superficial infection, pyocutaneous disease.
Radix Angelicae Dahuricae is dried root of Angelica dahurica or Angelica dahurica of Umbelliferae. Pungent flavor and warm nature. It enters lung, spleen and stomach meridians. Has the functions of relieving exterior syndrome, dispelling cold, dispelling pathogenic wind, relieving pain, dredging nasal orifice, eliminating disease, removing dampness, eliminating dampness, stopping leukorrhagia, dispelling pathogenic wind, relieving itching, relieving swelling, expelling pus, promoting granulation, promoting blood circulation, relieving pain, etc. Can be used for treating wind-cold type common cold, headache, rhinitis, and toothache. Rheumatic arthralgia, nasosinusitis, leucorrhea with reddish discharge, pain, furuncle, and pyogenic infections.
Radix scrophulariae is root of Scrophularia ningpoensis Fisch of Scrophulariaceae. Alias: radix scrophulariae, and radix scrophulariae. Is bitter and salty in taste. Slightly cold in nature. Is nontoxic. The main treatment is as follows: fever, nutritional blood, fever, polydipsia, crimson tongue, macula, bone-steaming, overstrain cough, restlessness, constipation due to body fluid deficiency, dryness and dim eyesight, sore throat, scrofula, subcutaneous nodule, superficial infection and sore toxicity.
The radix et rhizoma Rhei is dried root and rhizome of Rheum palmatum L, Rheum tanguticum Maxim. ex Baif. or Rheum officinale Baill. of Polygonaceae. Collecting and digging stems and leaves at late autumn or before germination in spring, removing thin roots, scraping outer skin, cutting into sections or segments, stringing, and drying or directly drying. Nature and taste: bitter and cold. Has the functions of purging excess heat, promoting the flow of food retention, removing blood stasis and removing toxic material. Can be used for treating excessive heat constipation, abdominal pain due to stagnation, jaundice due to damp-heat pathogen, acute appendicitis, incomplete intestinal obstruction, amenorrhea due to blood stasis, carbuncle, furuncle, suppurative dermatoses, burn, and scald. Raw rhubarb refers to decoction pieces of crude medicinal materials. Has the main functions of removing food retention and relieving constipation, and is used for treating excess heat in stomach and intestine and constipation.
The radix Paeoniae Rubra is dried root of Paeonia lactiflora pall or Paeonia veitchii Schott of Ranunculaceae. Bitter in taste and slightly cold in nature. It enters liver meridian. Has the effects of clearing heat, cooling blood, promoting blood circulation and removing blood stasis. Can be used for treating heat entering nutrient-blood, toxic heat macula, hematemesis and epistaxis, conjunctival congestion, swelling and pain, liver depression, hypochondriac pain, amenorrhea, dysmenorrhea, abdominal pain, traumatic injury, carbuncle, swelling, and pyocutaneous disease.
The Glycyrrhrizae radix is dried root and rhizome of Glycyrrhiza uralensis Fisch, Glycyrrhiza inflata Bat, or Glycyrrhiza glabra L. Sweet in flavor and neutral in nature. Has the effects of invigorating spleen and replenishing qi, clearing away heat and toxic materials, eliminating phlegm and stopping cough, relieving spasm and pain, and harmonizing the medicines. It is indicated for spleen and stomach deficiency, lassitude and hypodynamia, palpitation and shortness of breath, cough with profuse sputum, spasm and pain of abdomen and limbs, carbuncle and sore, and to relieve toxicity and strong action of drugs.
The Olibanum is resin exuded from bark of Boswellia carterii Birdw of Burseraceae and Boswellia bhauradaijiana Birdw of the same genus. The product is in the form of long oval emulsion, round-like granule or irregular block with different sizes. The major ones are up to 2cm (Boswellia carterii bead) or 5cm (Boswellia carterii). The surface is yellowish white and semitransparent, and is darkened after long-term storage by yellowish white powder. It is brittle and softened by heat. The fracture surface has a glass-like or wax-like luster. Has special fragrance and slightly bitter taste. It is usually processed by vinegar-moxibustion. Pungent, bitter and warm in nature. Has effects of promoting blood circulation, activating qi-flowing, relieving pain, eliminating swelling and promoting granulation. Can be used for treating thoracic obstruction, cardialgia, epigastralgia, dysmenorrhea, amenorrhea, puerperal blood stasis, abdominal pain, rheumatic arthralgia, spasm of muscles and tendons, traumatic injury, carbuncle, swelling, and pyocutaneous disease.
The Myrrha is dried resin of Commiphora myrrha Engl. or Commiphora molmol Engl. of Burseraceae. Is divided into natural myrrh and colloid myrrh. Pungent and bitter in flavor and mild in nature. Has the effects of removing blood stasis, relieving pain, eliminating swelling and promoting granulation. It is often used for treating thoracic obstruction, heart pain, epigastric pain, dysmenorrhea, amenorrhea, postpartum stasis, abdominal mass, rheumatic arthralgia, traumatic injury, carbuncle, swelling, sore and ulcer.
Sanguis Draxonis is resin exuded from fruit of daemonorops draco of Palmaceae. Sweet, salty and neutral in nature. Has effects of promoting blood circulation, relieving pain, removing blood stasis, stopping bleeding, promoting granulation, and healing sore. Can be used for treating traumatic injury, heart and abdomen blood stasis and pain, traumatic hemorrhage, and unhealed skin and external diseases.
The Plumbum Preparatium is prepared from pure lead. Pungent flavor and slightly cold in nature. Has the effects of removing toxic substances and putrefaction, astringing dampness and promoting wound healing, eliminating phlegm and relieving convulsion. It is commonly used for abscess, deep-rooted carbuncle, sores and ulcers, external hemorrhoid, eczema, burn and scald.
The beeswax is prepared by squeezing dried honey from honeycomb constructed by worker bee, and decocting in water. Contains a large amount of active ingredients and acidic substances. Has astringent, sore healing, granulation promoting, and analgesic effects. It is indicated for unhealed ulcer, wound, burn and scald.
The white gum is white gum incense, and is resin of resina Liquidambaris of Hamamelidaceae. The main functional indications are as follows: promoting blood circulation, cooling blood, removing toxic substance and relieving pain. It is indicated for abscess, deep-rooted carbuncle, sores and scabies, urticaria, scrofula, incised sores, toothache, hematemesis and epistaxis.
Borneolum, named as Borneolum, pericarpium Citri Tangerinae, folium Artemisiae Argyi, Borneolum Syntheticum, Serissa, Borneolum Syntheticum, and Borneolum Syntheticum, is prepared from stems and leaves of blumea balsamifera of Compositae or branches and leaves of Cinnamomum camphora of Lauraceae by steam distillation and recrystallization. Pungent, bitter and slightly cold in flavor; heart, liver and lung meridians entered; the product has effects of inducing resuscitation, refreshing mind, clearing heat, removing toxic substance, improving eyesight, and removing nebula, and can be used for treating fever, hyperpyrexia, coma, apoplexy, phlegm syncope, convulsion, summer-heat dampness covering resuscitation, pharyngitis, deafness, aphtha, swelling of teeth, skin ulcer, carbuncle, malnutritional hemorrhoid, conjunctival congestion, swelling and pain, nebula, and eye covering. For phlegm-fire stagnation, throat impediment, hoarseness, or heat accumulation, mouth sores and swollen teeth, borneol can be combined with cinnabar, borax and glauber salt to blow on the affected part to dissipate fire and remove toxicity. For coma due to heat block, Bing pian can be combined with she Xiang, niu Huang, Huang Lian and Yu jin to clear heat and induce resuscitation. For sudden fire or pterygium, Bing pian can be combined with Lian Gao Shi, Xuan Ming powder and Borax to make eyes in powder.
The Moschus is dry secretion of mature male sachet of forest musk deer moschus berezovski Flerov, horse musk deer M.sifanicus Przewalski or original musk deer M.moscheffersus Linnaeus. Has effects of inducing resuscitation, refreshing mind, promoting blood circulation, dredging channels, and relieving swelling and pain. It can be used for treating block syndrome of unconsciousness, pyocutaneous disease, toxic swelling, scrofula, subcutaneous nodule, sore throat, amenorrhea due to blood stasis, abdominal mass, heart and abdomen pain, headache, traumatic injury, arthralgia due to wind-cold-dampness, dystocia, dead fetus, and retained afterbirth.
Medulla Junci is dry stem pith of Juncus effusus L. of Juncus of Juncaceae, and is used for extracting core or air drying and cutting into pieces. Sweet and bland in flavor, slightly cold in nature. Has effects of clearing heart fire and promoting urination. Can be used for treating vexation, insomnia, oliguria, odynuria, aphtha of the mouth and tongue
The sesame oil is sesame oil, which is fatty oil extracted from seed of semen Sesami of Pedaliaceae. The main functional indications are as follows: moisten dryness and relax bowels, remove toxicity and promote tissue regeneration. Sweet taste and cool nature. Has effects in moistening dryness, relieving constipation, removing toxic materials, and promoting granulation. It is indicated for constipation due to intestinal dryness, ascarid, abdominal pain due to dyspepsia, sore, ulcer, scabies, tinea, and chapped skin. Rihuazi Bencao: the old oil is decocted into paste, promotes tissue regeneration and flesh growth, relieves pain, eliminates carbuncle and swelling, and tonifies skin cracks.
By adopting the technical scheme, the invention better realizes the aim of the invention, has scientific and reasonable formula and preparation process, supplements each other, and can effectively improve the utilization rate and the drug effect of the formula; the minium which has the function of the adhesive can also combine the effective components in the traditional Chinese medicine with the minium to enable the effective components to be in closer contact with pores, and the effective components can quickly permeate the pores to enter local blood circulation; the external transdermal absorption has no first-pass effect and high drug utilization rate; the black plaster matrix has mild drug property, and effectively reduces skin allergy and anaphylactic reaction; the traditional Chinese medicine composition has the same analgesic effect as the oral medicine, is safer, has small side effect and greatly reduces the incidence rate of adverse reactions; can be applied to the affected part for a long time, and has lasting effect; has good analgesic and anti-inflammatory effects.
Detailed Description
The present invention will be further described with reference to the following examples.
Example 1:
a black plaster suitable for acute soft tissue injury is prepared from the following raw materials in parts by weight:
the formula I is as follows: 25 to 35g of angelica, 25 to 35g of angelica dahurica, 25 to 35g of radix scrophulariae, 25 to 35g of rhubarb, 25 to 35g of red peony root and 25 to 35g of liquorice;
and the formula II comprises: 150 to 250g of myrrh, 150 to 250g of dragon's blood, 150 to 250g of yellow wax, 150 to 250g of white glue and 200 to 300g of red lead;
the formula III is as follows: 40 to 60g of borneol, 40 to 60g of musk, 40 to 60g of frankincense, 40 to 60g of myrrh and 40 to 60g of rush;
600-700 g of sesame oil (in the embodiment, the first formula comprises 30g of angelica sinensis, 30g of angelica dahurica, 30g of radix scrophulariae, 25g of rheum officinale, 30g of red peony root and 25g of liquorice, the second formula comprises 200g of myrrh, 200g of dragon's blood, 250g of yellow wax, 250g of white glue and 200g of red lead, and the third formula comprises 50g of borneol, 45g of musk, 60g of frankincense, 60g of myrrh, 50g of juncus effuses and 700g of sesame oil).
The rhubarb of the invention is raw rhubarb.
The preparation method of the black plaster suitable for acute soft tissue injury comprises the following steps:
the technical scheme includes that the first-component raw material medicines (Chinese angelica, dahurian angelica root, figwort root, raw rhubarb, red paeony root and liquoric root) are crushed and mixed according to a ratio, and an obtained first-component medicine mixture is put into sesame oil in a container and is uniformly stirred;
heating the oil-medicine mixture in the container and heating the oil-medicine mixture in the container, and continuously stirring the mixture to ensure that the composition-medicine mixture in the sesame oil is heated uniformly and fried to be withered and yellow (the oil color is dark brown, the inner part is scorched and the oil is not carbonized), and filtering dregs of the medicine to obtain filtered oil;
thirdly, adding the second raw material medicine (myrrh, dragon's blood, yellow wax and white glue) into the oil filter obtained in the second step according to the proportion, and decocting to obtain the medicinal oil;
fourthly, the medicinal oil is continuously heated and continuously stirred to promote the evaporation of the oxides generated by the medicinal oil in the step three and the medicinal mixture in the formula two, so that impurities in the medicinal oil are reduced to the minimum extent, and the quality of the ointment is improved; then, the lead is separated from the fire, evenly sieved and stirred along one direction, so that the lead is combined with the medicinal oil, and the lead is prevented from floating on the oil surface or precipitating at the bottom, and fully reacts;
fifthly, pouring the obtained ointment into water for soaking for removing fire toxin, avoiding skin irritation, erythema, pruritus and even blistering ulcer, and condensing for later use;
sixthly, crushing the three raw materials (borneol, musk, frankincense, myrrh and juncus effusus) into fine powder, mixing uniformly, and sieving, wherein the condensed ointment obtained in the step is divided according to the parts by weight for later use;
taking the ointment out of the water, heating and melting the ointment to remove water vapor, adding the ointment into the medicinal powder obtained in the step sixteenth according to the ratio, and uniformly stirring; spreading and coating to obtain the finished product.
The first bulk drug of the composition is prepared from 25-35 g of Chinese angelica, 25-35 g of angelica dahurica, 25-35 g of radix scrophulariae, 25-35 g of rheum officinale, 25-35 g of red peony roots, 25-35 g of liquorice and 600-700 g of sesame oil (in the embodiment, 30g of Chinese angelica, 30g of angelica dahurica, 30g of radix scrophulariae, 25g of rheum officinale, 30g of red peony roots, 25g of liquorice and 700g of sesame oil); the formula II in the step III comprises 150-250 g of myrrh, 150-250 g of dragon's blood, 150-250 g of beeswax, 150-250 g of white glue and 200-300 g of red lead (200 g of myrrh, 200g of dragon's blood, 250g of beeswax, 250g of white glue and 200g of red lead in the embodiment); the formula III in the step VI is prepared from 40g to 60g of borneol, 40g to 60g of musk, 40g to 60g of frankincense, 40g to 60g of myrrh and 40g to 60g of rush (in the embodiment, 50g of borneol, 45g of musk, 60g of frankincense, 60g of myrrh and 50g of rush).
In the steps, sesame oil is preheated to 40-80 ℃ before a medicine mixture in a composition is put into the sesame oil; after the composition I medicine mixture is put into sesame oil, soaking for 1 hour to 1.5 hours (1.5 hours in the embodiment) under the condition of 90 ℃ to 100 ℃ (90 ℃ in the embodiment), wherein the heat preservation mode is to heat the container and the oil-medicine mixture in the container in a water bath manner, so that the situation that hard parts in the composition I medicine mixture are not penetrated and the medicine effect cannot be fully exerted is avoided; heating the sesame oil to 220-240 ℃ (230 ℃ in the embodiment) for 1-3.5 hours (3 hours in the embodiment).
The step of the invention comprises soaking the Chinese medicinal paste in water for 24 hours; the melting temperature of the stephania ointment is not more than 100 ℃ (70 ℃ in the embodiment).
Example 2:
a black plaster suitable for acute soft tissue injury is prepared from the following raw materials in parts by weight:
the formula I is as follows: 30 to 35g of angelica, 25 to 30g of angelica dahurica, 30 to 35g of radix scrophulariae, 25 to 30g of rhubarb, 30 to 35g of red peony root and 25 to 30g of liquorice;
and the formula II comprises: 200 to 250g of myrrh, 180 to 200g of dragon's blood, 200 to 250g of yellow wax, 220 to 250g of white glue and 200 to 250g of red lead;
the formula III is as follows: 45 to 55g of borneol, 45 to 50g of musk, 50 to 60g of frankincense, 50 to 60g of myrrh and 50 to 60g of rush;
630-700 g of sesame oil (in the embodiment, 35g of angelica, 25g of angelica dahurica, 35g of radix scrophulariae, 30g of rhubarb, 35g of red peony root and 30g of liquorice, 250g of myrrh, 180g of dragon's blood, 200g of beeswax, 220g of white glue and 250g of red lead, and third formula, 55g of borneol, 50g of musk, 50g of frankincense, 50g of myrrh, 60g of rush and 630g of sesame oil).
According to the preparation method of the black plaster suitable for acute soft tissue injury, the first raw material of the formula in the step is prepared from 25-35 g of angelica, 25-35 g of angelica dahurica, 25-35 g of radix scrophulariae, 25-35 g of rheum officinale, 25-35 g of red peony roots, 25-35 g of liquorice and 600-700 g of sesame oil (in the embodiment, 35g of angelica, 25g of angelica dahurica, 35g of radix scrophulariae, 30g of rheum officinale, 35g of red peony roots, 30g of liquorice and 630g of sesame oil); the formula II in the step III comprises 150-250 g of myrrh, 150-250 g of dragon's blood, 150-250 g of beeswax, 150-250 g of white glue and 200-300 g of red lead (in this embodiment, 250g of myrrh, 180g of dragon's blood, 200g of beeswax, 220g of white glue and 250g of red lead); the formula III in the step VI is prepared from 40g to 60g of borneol, 40g to 60g of musk, 40g to 60g of frankincense, 40g to 60g of myrrh and 40g to 60g of rush (in the embodiment, 55g of borneol, 50g of musk, 50g of frankincense, 50g of myrrh and 60g of rush).
In the steps, sesame oil is preheated to 40-80 ℃ before a medicine mixture in a composition is put into the sesame oil; after the composition I medicine mixture is put into sesame oil, soaking for 1 hour to 1.5 hours (1.5 hours in the embodiment) under the condition of 90 ℃ to 100 ℃ (95 ℃ in the embodiment), wherein the heat preservation mode is to heat the container and the oil-medicine mixture in the container in a water bath manner, so that the situation that hard parts in the composition I medicine mixture are not penetrated and the medicine effect cannot be fully exerted is avoided; heating the sesame oil to 220-240 ℃ (220 ℃ in the embodiment) for 1-3.5 hours (3.5 hours in the embodiment).
The step of the invention comprises soaking the Chinese medicinal paste in water for 24 hours; the melting temperature of the stephania ointment is not more than 100 ℃ (80 ℃ in the embodiment).
The same as in example 1.
Example 3:
a black plaster suitable for acute soft tissue injury is prepared from the following raw materials in parts by weight:
the formula I is as follows: 30 to 35g of angelica, 25 to 30g of angelica dahurica, 30 to 35g of radix scrophulariae, 25 to 30g of rhubarb, 30 to 35g of red peony root and 25 to 30g of liquorice;
and the formula II comprises: 200 to 250g of myrrh, 180 to 200g of dragon's blood, 200 to 250g of yellow wax, 220 to 250g of white glue and 200 to 250g of red lead;
the formula III is as follows: 45 to 55g of borneol, 45 to 50g of musk, 50 to 60g of frankincense, 50 to 60g of myrrh and 50 to 60g of rush;
630-700 g of sesame oil (in this embodiment, 25g of angelica, 35g of angelica dahurica, 25g of radix scrophulariae, 35g of rhubarb, 25g of red peony root and 35g of liquorice, 150g of myrrh, 150g of dragon's blood, 150g of beeswax, 150g of white glue and 200g of red lead, and third formula, 40g of borneol, 40g of musk, 40g of frankincense, 40g of myrrh, 40g of rush and 600g of sesame oil).
According to the preparation method of the black plaster suitable for acute soft tissue injury, the first raw material of the formula in the step is prepared from 25-35 g of angelica, 25-35 g of angelica dahurica, 25-35 g of radix scrophulariae, 25-35 g of rheum officinale, 25-35 g of red peony roots, 25-35 g of liquorice and 600-700 g of sesame oil (in the embodiment, 25g of angelica, 35g of angelica dahurica, 25g of radix scrophulariae, 35g of rheum officinale, 25g of red peony roots, 35g of liquorice and 600g of sesame oil); the formula II in the step III comprises 150-250 g of myrrh, 150-250 g of dragon's blood, 150-250 g of beeswax, 150-250 g of white glue and 200-300 g of red lead (in this embodiment, 150g of myrrh, 150g of dragon's blood, 150g of beeswax, 150g of white glue and 200g of red lead); the formula III in the step VI is prepared from 40g to 60g of borneol, 40g to 60g of musk, 40g to 60g of frankincense, 40g to 60g of myrrh and 40g to 60g of rush (in the embodiment, 40g of borneol, 40g of musk, 40g of frankincense, 40g of myrrh and 40g of rush).
In the steps, sesame oil is preheated to 40-80 ℃ before a medicine mixture in a composition is put into the sesame oil; after the composition I medicine mixture is put into sesame oil, soaking for 1 hour to 1.5 hours (1 hour in the embodiment) at the temperature of 90 ℃ to 100 ℃ (100 ℃ in the embodiment), wherein the heat preservation mode is to heat the container and the oil-medicine mixture in the container in a water bath manner, so that hard parts in the composition I medicine mixture are prevented from being not penetrated, and the medicine effect cannot be fully exerted; heating the sesame oil to 220-240 ℃ (240 ℃ in the embodiment) for 1-3.5 hours (1 hour in the embodiment).
The same as in example 1.
Example 4:
a black plaster suitable for acute soft tissue injury is prepared from the following raw materials in parts by weight:
the formula I is as follows: 30 to 35g of angelica, 25 to 30g of angelica dahurica, 30 to 35g of radix scrophulariae, 25 to 30g of rhubarb, 30 to 35g of red peony root and 25 to 30g of liquorice;
and the formula II comprises: 200 to 250g of myrrh, 180 to 200g of dragon's blood, 200 to 250g of yellow wax, 220 to 250g of white glue and 200 to 250g of red lead;
the formula III is as follows: 45 to 55g of borneol, 45 to 50g of musk, 50 to 60g of frankincense, 50 to 60g of myrrh and 50 to 60g of rush;
630-700 g of sesame oil (35 g of angelica sinensis, 35g of angelica dahurica, 35g of radix scrophulariae, 30g of rheum officinale, 35g of red peony root and 35g of liquorice in the embodiment), 250g of myrrh, 250g of dragon's blood, 250g of beeswax, 250g of white glue and 300g of red lead in the formula II, 60g of borneol, 60g of musk, 60g of frankincense, 60g of myrrh, 55g of juncus effuses and 650g of sesame oil in the formula III).
According to the preparation method of the black plaster suitable for acute soft tissue injury, the first raw material of the formula in the step is prepared from 25-35 g of angelica, 25-35 g of angelica dahurica, 25-35 g of radix scrophulariae, 25-35 g of rheum officinale, 25-35 g of red peony roots, 25-35 g of liquorice and 600-700 g of sesame oil (in the embodiment, 35g of angelica dahurica, 35g of radix scrophulariae, 30g of rheum officinale, 35g of red peony roots, 35g of liquorice and 650g of sesame oil); the formula II in the step III comprises 150-250 g of myrrh, 150-250 g of dragon's blood, 150-250 g of beeswax, 150-250 g of white glue and 200-300 g of red lead (in this embodiment, 250g of myrrh, 250g of dragon's blood, 250g of beeswax, 250g of white glue and 300g of red lead); the formula III in the step VI is prepared from 40g to 60g of borneol, 40g to 60g of musk, 40g to 60g of frankincense, 40g to 60g of myrrh and 40g to 60g of rush (in the embodiment, 60g of borneol, 60g of musk, 60g of frankincense, 60g of myrrh and 55g of rush).
In the steps, sesame oil is preheated to 40-80 ℃ before a medicine mixture in a composition is put into the sesame oil; after the composition I medicine mixture is put into sesame oil, soaking for 1 hour to 1.5 hours (1.5 hours in the embodiment) under the condition of 90 ℃ to 100 ℃ (95 ℃ in the embodiment), wherein the heat preservation mode is to heat the container and the oil-medicine mixture in the container in a water bath manner, so that the situation that hard parts in the composition I medicine mixture are not penetrated and the medicine effect cannot be fully exerted is avoided; heating the sesame oil to 220-240 ℃ (230 ℃ in the embodiment) for 1-3.5 hours (2.5 hours in the embodiment).
The same as in example 3.
Test examples
1 Material
1.1 animals
30 ICR mice, each half weight (180. + -.20) g, were purchased from Tianqin laboratory animals Co., Ltd, Hunan. Feeding in cage under light/dark cycle of 12h/12h (illumination time of 7: 00-19: 00), and freely obtaining feed and drinking water. License of experimental animal: SYKX 2020 (Xiang) 0008.
1.2 drugs and reagents
Raw medicinal powder provided by a preparation room of the institute of traditional Chinese medicine of Hunan province is prepared according to the proportion of example 1, and the production batch number is as follows: 20210902, respectively;
positive control group drug, aspirin tablet, beijing nova pharmaceuticals ltd, national drug standard H10980297, lot No. 20210127;
glacial acetic acid.
1.3 instruments
A hot plate apparatus;
model ME-202 electronic balance.
2 method of experiment
2.1 Hot plate analgesia test
2.1.1 preselection of animals
The mice are placed in a hot plate instrument, the temperature is set to be 55 +/-0.5 ℃, the pain threshold value of the mice is measured for 2 times, the feet of the mice after licking are used as an observation index, and the mice with pain reaction within 30s are preselected.
2.1.2 grouping and administration
30 mice that were eligible for preselection were selected and randomly divided into 3 groups: blank control group and positive control group (aspirin 0.11 g.kg)-1) And plaster prescription (plaster prescription 0.90. kg)-1);
Removing the back rat hair of all mice by adopting a 10% sodium sulfide solution, and using an aspirin tablet water solution for positive control group; plaster formula of 2 x 2cm for external application2Gavage distilled water for 1 time and d for blank control group-1And continuously administering for 3 d.
2.1.3 pain threshold determination
After the last administration for 1h, the animals were placed in a hotplate apparatus and the time for the mice to lick the hindpaw was recorded, and if the mice did not have a painful reaction within 60s, the animals were immediately removed and counted for 60 s.
2.1.4 pain threshold calculation
After the test was completed, the pain threshold (hot pain response time) and the pain threshold increase percentage of each group of mice were calculated.
2.2 acetic acid writhing method
2.1.2 grouping and administration
30 mice that were eligible for preselection were selected and randomly divided into 3 groups: model control group and positive control group (aspirin 0.11 g.kg)-1) And plaster prescription (plaster prescription 0.90 g.kg)-1);
Positive control group gastric perfusion aspirin tablet water solution; plaster formula of 2 x 2cm for external application2Gavage distilled water for 1 time and d for blank control group-1And continuously administering for 3 d.
2.1.3 Observation index
After the last administration for 1h, all animals were injected with 0.4ml of 0.6% glacial acetic acid solution in the abdominal cavity, and the number of animals with writhing reaction within 15min, the number of writhing times and the percentage of analgesia were recorded as evaluation indexes.
Percent analgesia (P) = (number of animals with no writhing response in experimental group-number of animals with no writhing response in control group)/number of animals with writhing response in control group 100.
3 statistical treatment
The data analysis uses statistical software SPSS17.0, all measured data with (S) between groups, One-way-ANOVA, t-test, two-sided test, pairwise comparison, P<0.05 is significant in difference and has statistical significance.
4 results
4.1 Effect of the ointment formulation on the response to thermal pain in ICR mice
Compared with a blank control group, the pain threshold values of mice in the positive control group and the plaster prescription group are obviously increased, and the difference is shown by the statistical significance: (PLess than 0.01), the pain threshold increasing percentage of the positive control group and the plaster prescription group are respectively 26.1 percent and 25.7 percent.
Compared with blank group,* P <0.05,** P <0.01
Compared with the model control group, the torsion rates of the positive control group and the plaster prescription group of the mice are respectively 80%, 30% and 50%, and the pain rates of the positive control group and the plaster prescription group are respectively 62% and 38%. Compared with the model control group, the times of torsion of the positive control group and the plaster square group mice are obviously reduced, and the difference is statistically significant (P< 0.05), the results are shown in Table 2.
Compared with model group,# P <0.05,## P <0.01
5 conclusion
The invention can obviously increase the thermal pain threshold of a mouse, and the pain threshold is increased by 25.7 percent and is similar to the analgesic effect of the positive control drug aspirin by 26.1 percent. The plaster formula can reduce the body twisting rate and the body twisting times of a mouse in an acetic acid body twisting experiment.
In conclusion, the invention has better analgesic effect.
Claims (10)
1. The black plaster for acute soft tissue injury is characterized by being prepared from the following raw materials in parts by weight:
the formula I is as follows: 25 to 35g of angelica, 25 to 35g of angelica dahurica, 25 to 35g of radix scrophulariae, 25 to 35g of rhubarb, 25 to 35g of red peony root and 25 to 35g of liquorice;
and the formula II comprises: 150 to 250g of myrrh, 150 to 250g of dragon's blood, 150 to 250g of yellow wax, 150 to 250g of white glue and 200 to 300g of red lead;
the formula III is as follows: 40 to 60g of borneol, 40 to 60g of musk, 40 to 60g of frankincense, 40 to 60g of myrrh and 40 to 60g of rush;
600-700 g of sesame oil.
2. The black plaster for acute soft tissue injury according to claim 1, wherein the raw materials in the ratio are:
the formula I is as follows: 30 to 35g of angelica, 25 to 30g of angelica dahurica, 30 to 35g of radix scrophulariae, 25 to 30g of rhubarb, 30 to 35g of red peony root and 25 to 30g of liquorice;
and the formula II comprises: 200 to 250g of myrrh, 180 to 200g of dragon's blood, 200 to 250g of yellow wax, 220 to 250g of white glue and 200 to 250g of red lead;
the formula III is as follows: 45 to 55g of borneol, 45 to 50g of musk, 50 to 60g of frankincense, 50 to 60g of myrrh and 50 to 60g of rush;
630-700 g of sesame oil.
3. The black plaster for acute soft tissue injury according to claim 1 or 2, wherein the raw materials in the ratio are:
the formula I is as follows: 30g of angelica, 30g of angelica dahurica, 30g of radix scrophulariae, 25g of rhubarb, 30g of red peony root and 25g of liquorice;
and the formula II comprises: 200g of myrrh, 200g of dragon's blood, 250g of yellow wax, 250g of white glue and 200g of red lead;
the formula III is as follows: 50g of borneol, 45g of musk, 60g of frankincense, 60g of myrrh and 50g of juncus effuses;
700g of sesame oil.
4. A black plaster for acute soft tissue injury according to claim 1 or 2, wherein the rhubarb is raw rhubarb.
5. A black plaster for acute soft tissue injury according to claim 3, wherein the rhubarb is raw rhubarb.
6. A preparation method of a black plaster suitable for acute soft tissue injury is characterized by comprising the following steps:
the technical scheme includes that the first group of raw material medicines are crushed and mixed according to a ratio, and an obtained first group of medicine mixture is put into sesame oil and stirred uniformly;
heating and raising the temperature, continuously stirring, frying the composition-medicine mixture in the sesame oil to be withered and yellow, and filtering out dregs of a decoction to obtain filtered oil;
the second raw material medicine is added into the oil filter obtained in the step II according to the proportion, and the mixture is decocted into dripping pills to obtain medicinal oil;
fourthly, the medicinal oil is continuously heated and continuously stirred to reduce impurities in the medicinal oil, then the medicinal oil is separated from fire, lead is uniformly sieved in the medicinal oil, and the medicinal oil is stirred in one direction to fully react;
pouring the ointment obtained after the reaction is finished into water for soaking, condensing and dividing for later use;
sixthly, crushing the three raw materials of the formula into fine powder, uniformly mixing the fine powder and the fine powder, and dividing the mixture into parts according to the proportion for later use;
taking the ointment out of the water, heating and melting the ointment, adding the ointment into the medicinal powder obtained in the step sixteenth according to the ratio, and uniformly stirring the mixture; spreading and coating to obtain the finished product.
7. The preparation method of a black plaster suitable for acute soft tissue injury according to claim 6, characterized in that the first raw material medicine in the step is prepared from 25 to 35g of angelica sinensis, 25 to 35g of angelica dahurica, 25 to 35g of radix scrophulariae, 25 to 35g of rheum officinale, 25 to 35g of red peony root, 25 to 35g of licorice root, and 600 to 700g of sesame oil; the formula II in the step III comprises 150-250 g of myrrh, 150-250 g of dragon's blood, 150-250 g of yellow wax, 150-250 g of white glue and 200-300 g of red lead; the formula III in the step VI is prepared from 40g to 60g of borneol, 40g to 60g of musk, 40g to 60g of frankincense, 40g to 60g of myrrh and 40g to 60g of rush.
8. A preparation method of a black plaster suitable for acute soft tissue injury according to claim 6, characterized in that in the step of first, before a medicine mixture of a composition is put in, sesame oil is preheated to 40-80 ℃; the formula I medicine mixture is put into sesame oil and then is soaked for 1 to 1.5 hours at the temperature of between 90 and 100 ℃, and the heat preservation mode is water bath heating.
9. A method for preparing a black plaster suitable for acute soft tissue injury according to claim 7, wherein in the step of adding a composition-a drug mixture, sesame oil is preheated to 40 ℃ to 80 ℃; the formula I medicine mixture is put into sesame oil and then is soaked for 1 to 1.5 hours at the temperature of between 90 and 100 ℃, and the heat preservation mode is water bath heating.
10. The preparation method of the black plaster for acute soft tissue injury according to claim 6, 7, 8 or 9, characterized in that the step of soaking the Chinese medicinal plaster in water for 24 hours; the temperature for heating and melting the stephania ointment is not more than 100 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111230297.7A CN113925846A (en) | 2021-10-22 | 2021-10-22 | Black plaster suitable for acute soft tissue injury and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111230297.7A CN113925846A (en) | 2021-10-22 | 2021-10-22 | Black plaster suitable for acute soft tissue injury and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113925846A true CN113925846A (en) | 2022-01-14 |
Family
ID=79283623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111230297.7A Pending CN113925846A (en) | 2021-10-22 | 2021-10-22 | Black plaster suitable for acute soft tissue injury and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113925846A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101791364A (en) * | 2010-04-28 | 2010-08-04 | 董崇孝 | Traditional Chinese medicine composition capable of promoting wound healing and preparation method thereof |
CN105796744A (en) * | 2016-03-29 | 2016-07-27 | 李绍斌 | Toxin-removal traditional Chinese medicine ointment |
CN112057506A (en) * | 2019-05-21 | 2020-12-11 | 魏红举 | Black plaster and preparation method thereof |
-
2021
- 2021-10-22 CN CN202111230297.7A patent/CN113925846A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101791364A (en) * | 2010-04-28 | 2010-08-04 | 董崇孝 | Traditional Chinese medicine composition capable of promoting wound healing and preparation method thereof |
CN105796744A (en) * | 2016-03-29 | 2016-07-27 | 李绍斌 | Toxin-removal traditional Chinese medicine ointment |
CN112057506A (en) * | 2019-05-21 | 2020-12-11 | 魏红举 | Black plaster and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103505656B (en) | Chinese medicine preparation for treating stomatitis | |
CN102370910A (en) | Wart treating medicament and preparation method thereof | |
CN105250940A (en) | Traditional Chinese medicinal plaster for treating stomachache diseases, and preparation method thereof | |
CN101518600B (en) | Chinese medicinal composition for treating bacterial or fungal dermatosis and preparation method thereof | |
CN107670092A (en) | A kind of sanitary napkin with healthcare function | |
CN106389881A (en) | Ointment capable of invigorating blood circulation and dissipating blood stasis | |
CN102552737B (en) | Quick and effective bleeding arresting Chinese medicinal tincture | |
CN101874850A (en) | Medicament for treating chronic urticaria | |
CN103845616A (en) | Pharmaceutical composition for eliminating inflammation and disinfecting | |
CN104274662A (en) | Itching treating medicine | |
CN113925846A (en) | Black plaster suitable for acute soft tissue injury and preparation method thereof | |
CN103656581A (en) | Traditional Chinese medicine composition for treating chilblain and preparation method thereof | |
CN105232849A (en) | Plaster for treating burns | |
CN100423767C (en) | Medicine for curing burn and scald wound and its preparation method | |
CN109908312B (en) | Hemorrhoid ointment and preparation method thereof | |
CN108066738B (en) | Ointment for treating gouty arthritis and preparation method thereof | |
CN105561229A (en) | Menstruation delaying treatment medicine | |
CN105412244A (en) | Traditional Chinese medicine composition treating gynecological cervicitis | |
CN104189195B (en) | The Traditional Chinese medicine medicated bath for the treatment of neurotic skin pruritus and preparation method | |
CN104352773A (en) | Traditional Chinese medicine preparation for treating chronic bronchitis and bronchial asthma | |
CN112972563A (en) | Composition for treating long-term menstruation, preparation method and application | |
CN111905078A (en) | A Chinese medicinal composition for treating gout | |
CN116077388A (en) | Acne-removing Chinese herbal medicine composition and preparation method and application thereof | |
CN117323263A (en) | Traditional Chinese medicine extraction composition with relieving function and application thereof | |
CN114129669A (en) | Cataplasm patch for treating rheumatism and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220114 |